Nathan Rice
Stock Analyst at Piper Sandler
(3.07)
# 1,210
Out of 4,898 analysts
53
Total ratings
54.55%
Success rate
10.27%
Average return
Main Sectors:
Stocks Rated by Nathan Rice
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BFC Bank First | Maintains: Neutral | $110 → $111 | $122.53 | -9.41% | 7 | Apr 17, 2025 | |
| MBIN Merchants Bancorp | Maintains: Overweight | $53 → $57 | $35.22 | +60.42% | 7 | Jan 30, 2025 | |
| FMBH First Mid Bancshares | Maintains: Overweight | $46 → $47 | $39.38 | +19.35% | 3 | Nov 1, 2024 | |
| BY Byline Bancorp | Reiterates: Overweight | $34 | $28.44 | +19.55% | 8 | Oct 29, 2024 | |
| CVS CVS Health | Maintains: Buy | $85 → $74 | $64.36 | +14.98% | 2 | May 2, 2024 | |
| NIC Nicolet Bankshares | Assumes: Neutral | $84 | $130.46 | -35.61% | 1 | Jan 10, 2024 | |
| ALGN Align Technology | Downgrades: Sell | $197 | $199.31 | -1.16% | 10 | Dec 11, 2023 | |
| ELAN Elanco Animal Health | Maintains: Sell | $11 → $9 | $14.89 | -39.56% | 1 | Apr 25, 2023 | |
| IDXX IDEXX Laboratories | Upgrades: Buy | $530 → $435 | $531.42 | -18.14% | 4 | Jul 21, 2022 | |
| CI The Cigna Group | Initiates: Neutral | $233 | $303.06 | -23.12% | 5 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $83 | $30.64 | +170.89% | 4 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $18.96 | -20.89% | 1 | Dec 19, 2019 |
Bank First
Apr 17, 2025
Maintains: Neutral
Price Target: $110 → $111
Current: $122.53
Upside: -9.41%
Merchants Bancorp
Jan 30, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $35.22
Upside: +60.42%
First Mid Bancshares
Nov 1, 2024
Maintains: Overweight
Price Target: $46 → $47
Current: $39.38
Upside: +19.35%
Byline Bancorp
Oct 29, 2024
Reiterates: Overweight
Price Target: $34
Current: $28.44
Upside: +19.55%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85 → $74
Current: $64.36
Upside: +14.98%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $130.46
Upside: -35.61%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $199.31
Upside: -1.16%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11 → $9
Current: $14.89
Upside: -39.56%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530 → $435
Current: $531.42
Upside: -18.14%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $303.06
Upside: -23.12%
Dec 14, 2021
Initiates: Neutral
Price Target: $83
Current: $30.64
Upside: +170.89%
Dec 19, 2019
Initiates: Overweight
Price Target: $15
Current: $18.96
Upside: -20.89%